The University of Colorado Anschutz Medical Campus will lead a groundbreaking national clinical trial-supported by a $29 million grant from Octapharma-to evaluate whether early replacement of fibrinogen, a critical blood clotting mechanism in the body, can improve outcomes for trauma patients experiencing life-threatening bleeding.